Skip to main content

Fiscal Wizard · Single-issue tearsheet

BMRN / Jun 21, 2026 Run #7504

BMRN

BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.

Composite verdict

D 32.1 / 100
Bearish setup · Reversal 11 drivers · 2 gates blocking
  • MACD Signal Cross
  • Chaikin Money Flow
  • Elder Force Index
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 157th of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: volatile range
Bull 0%Evidence: High · 16 signals100% Bear
Momentum Bearish 18Mean-reversion Neutral 41

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -31%
Asset value $31.49Earnings power value $20.67Price $54.69

Priced above its no-growth earnings power value ($20.67/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Above average

61.9 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Asset Turnover 99
OCF to Net Income 0
Return on Assets 84
Cash Conversion 0
Greenblatt ROC 83
EPS Growth (YoY) 0

Technicals Bearish

2.3 / 100

Bearish setup leads (MACD Signal Cross, Chaikin Money Flow, Elder Force Index); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
MACD Signal Cross 6
Chaikin Money Flow 8
Elder Force Index 9

Risk Gates

2 blocking 7 caution

2 guards active, 23 signals gated.

Realized Volatility Regime Blocking

High-vol regime mutes mean-reversion signals; low-vol regime mutes breakout signals.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Cash Ratio Caution

Visual cash-cushion flag — does not mute signals.

Current Ratio Caution

Visual liquidity flag — does not mute signals.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for BMRN.